一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
泛癌分析揭示 RCSD1 免疫浸润与人类肿瘤临床预后的关系
英文原题：Pan-cancer analysis reveals the relationship between RCSD1 immune infiltration and clinical prognosis in human tumors.
查看英文原题
Pan-cancer analysis reveals the relationship between RCSD1 immune infiltration and clinical prognosis in human tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
作为泛癌的预后生物标志物，RCSD1 与免疫浸润相关。
中文摘要
背景
RCSD1是一种细胞骨架调节因子，已证实在血液系统肿瘤中发生基因突变，但RCSD1在泛癌中的作用机制及其对患者预后的影响尚未研究。
方法
研究利用TCGA、GEPIA、UALCAN、Kaplan-Meier Plotter、Linkedomics、STRING、cBioPortal、TISIDB、TCIA和TIMER等数据库，分析RCSD1在人类肿瘤中的表达及其与临床预后、共表达网络功能、突变状态和肿瘤免疫浸润的关系，重点关注肺腺癌（LUAD）和肺鳞状细胞癌（LUSC）。
结果
与正常组织相比，多数肿瘤中RCSD1表达较低；RCSD1高表达与患者生存较好相关。RCSD1共表达网络主要参与免疫应答调控。在人类癌症中，RCSD1对肿瘤微环境（TME）具有重要作用，并与肺癌中的TIL（肿瘤浸润淋巴细胞）表达显著相关。
结论
RCSD1可作为泛癌预后生物标志物，并与免疫浸润相关。
展开英文摘要原文
BACKGROUND
RCSD1 is a cytoskeletal regulator that has been confirmed to undergo genetic mutations in hematological tumors, but the mechanisms of RCSD1 in pan-cancer and its impact on patient prognosis have not been studied.
METHODS
Using TCGA, GEPIA, UALCAN, Kaplan-Meier plotters, Linkedomics, String, cBioPortal, TISIDB, TCIA and TIMER database methods, we investigated the expression of RCSD1 in human tumors and its relationship to clinical prognosis, functional analysis of co-expression networks, mutation status, and immune infiltration in cancers, especially lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).
RESULTS
The expression of RCSD1 is low in most tumors compared with normal tissues, and its high expression is associated with good patient survival. The RCSD1 co-expression network is mainly involved in the regulation of immune response. In human cancer, RCSD1 plays an important role in the tumor microenvironment (TME) and is significantly associated with the expression of immune infiltrating cells (TIL) in lung cancer.
CONCLUSIONS
As a prognostic biomarker of generalized cancer, RCSD1 is associated with immune infiltration.
论文信息
- 作者
- Qiao H、Yin H、Feng Y、Tang H
- 单位
- Department of Respiratory Medicine, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 36311703 · DOI 10.3389/fimmu.2022.1008778
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →